Bottom line
ETHSX vs QAAGZX: the short answer
ETHSX (Eaton Vance Worldwide Health Sciences Fund) and QAAGZX (T. Rowe Price Health Sciences Portfolio) share a meaningful slice of their top holdings — about 64% by weight.
But QAAGZX is far broader, holding 277 positions to 42 for ETHSX, so beyond the top names it adds exposure ETHSX doesn't have.
QAAGZX is cheaper at 0.86% vs 1.18% — a difference of $32 a year per $10,000 invested.
Over five years, ETHSX returned +5.3% a year vs +4.1% for QAAGZX (reporting dates differ).
ETHSX has a front-end sales load of up to 5.25%; the other does not.
Updated Nov 19, 2026
ETHSX vs QAAGZX side by side
| ETHSX | QAAGZX | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Morgan Stanley | T. Rowe Price |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.18% | 0.86% |
| Annual cost per $10k | $118 | $86 |
| 10-yr cost on $10k (prospectus) | $1,911 | $1,061 |
| Max front load | 5.25% | None |
| 12b-1 fee | 0.25% | 0% |
| 1-yr return | −1.9% | +18.1% |
| 5-yr return (annualized) | +5.3% | +4.1% |
| 10-yr return (annualized) | +6.4% | +9.0% |
| Best quarter | +14.2% | +23.4% |
| Worst quarter | −12.1% | −15.8% |
| Net assets (fund) | $757.9M | $751.7M |
| Number of holdings | 42 | 277 |
| Portfolio turnover | 3% | 65% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | ETHSX | QAAGZX | Difference |
|---|---|---|---|
| 2024 | +3.5% | +1.7% | +1.9% |
| 2023 | +5.7% | +3.0% | +2.7% |
| 2022 | −9.4% | −12.5% | +3.0% |
| 2021 | +22.1% | +13.1% | +9.0% |
| 2020 | +13.0% | +29.6% | −16.6% |
| 2019 | +26.0% | +29.0% | −3.0% |
| 2018 | +6.0% | +1.1% | +4.9% |
| 2017 | +16.2% | +27.6% | −11.3% |
| 2016 | −14.9% | −10.5% | −4.4% |
Source: Fund prospectus bar charts
Holdings overlap
12 of ETHSX's top 25 holdings also appear in QAAGZX's top 25.
| Holding | ETHSX | QAAGZX |
|---|---|---|
| Eli Lilly & Co | 12.47% | 14.06% |
| AbbVie Inc | 6.46% | 5.12% |
| Johnson & Johnson | 6.45% | 6.64% |
| UnitedHealth Group Inc | 5.49% | 5.88% |
| Merck & Co Inc | 5.08% | 4.00% |
| Bristol-Myers Squibb Co | 4.25% | 2.12% |
| Vertex Pharmaceuticals Inc | 3.38% | 2.26% |
| Gilead Sciences Inc | 3.34% | 2.79% |
| Thermo Fisher Scientific Inc | 2.79% | 2.53% |
| Intuitive Surgical Inc | 2.72% | 1.89% |
| Stryker Corp | 2.21% | 1.78% |
| Abbott Laboratories | 1.65% | 1.91% |
Source: SEC Form N-PORT
ETHSX top 10
- Eli Lilly & Co — 12.47%
- AbbVie Inc — 6.46%
- Johnson & Johnson — 6.45%
- AstraZeneca PLC — 6.24%
- UnitedHealth Group Inc — 5.49%
- Roche Holding AG — 5.44%
- Merck & Co Inc — 5.08%
- Bristol-Myers Squibb Co — 4.25%
- Vertex Pharmaceuticals Inc — 3.38%
- Gilead Sciences Inc — 3.34%
QAAGZX top 10
- Eli Lilly & Co — 14.06%
- Johnson & Johnson — 6.64%
- Unitedhealth Group Inc — 5.88%
- Abbvie Inc — 5.12%
- Merck & Co. Inc. — 4.00%
- Gilead Sciences Inc — 2.79%
- Thermo Fisher Scientific Inc — 2.53%
- Vertex Pharmaceuticals Inc — 2.26%
- Bristol-myers Squibb Co — 2.12%
- Abbott Laboratories — 1.91%
FAQ
What is the difference between ETHSX and QAAGZX?
Which is cheaper, ETHSX or QAAGZX?
Should I own both ETHSX and QAAGZX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.